ArticlePediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2022
Short-acting β
Article in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 20 citations in OpenAlex.
- TET1 Protects the Lungs from Diesel Exhaust Particle-Induced Inflammation and Abnormal Function.Research square · 2026Article
- Treatable traits in paediatric bronchiectasis: current practice and a proposed checklist.European journal of pediatrics · 2026Article
- Climate change and respiratory health: implications for respiratory clinicians in primary and specialist care.NPJ primary care respiratory medicine · 2026Review
- Critical reappraisal of short-acting bronchodilators for pediatric respiratory diseases.Italian journal of pediatrics · 2024Review
- Uncontrolled asthma in school-aged children-a nationwide specialist care study.The journal of allergy and clinical immunology. Global · 2024Article
- Key Characteristics of Asthma Patients with COVID-19 Vary Substantially by Age.Journal of asthma and allergy · 2024Article
- Burden and unmet need for specialist care in poorly controlled and severe childhood asthma in a Danish nationwide cohort.Respiratory research · 2023Article
- Climate change and respiratory disease: clinical guidance for healthcare professionals.Breathe (Sheffield, England) · 2023Review
- Short-acting βERJ open research · 2023Article
- Short-acting βPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022Article
- Impact of family socioeconomic position on childhood asthma outcomes, severity, and specialist referral - a Danish nationwide study.Chronic respiratory diseaseArticle
- Real-world phenotyping and risk assessment of childhood asthma burden using national registries.Respiratory medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn adults and adolescents with asthma, use of ≥3 short-acting β
methodsThis population-based cohort study utilized linked data from the Swedish national healthcare registries involving patients with asthma (<18 years) treated in secondary care between 2006-2015. Exacerbation risk, by baseline SABA collection (0-2 vs. ≥3 canisters, further examined as ordinal/continuous variable) and stratified on comorbid atopic disease (allergic rhinitis, dermatitis and eczema, and food/other allergies), was assessed for 1-year follow-up using negative binomial regression.
resultsOf 219,561 patients assessed, 45.4%, 31.7%, and 26.5% of patients aged 0-5, 6-11, and 12-17 years, respectively, collected ≥3 SABA canisters during the baseline year (high use). Collection of ≥3 SABA canisters (vs. 0-2) was associated with increased exacerbation risk during follow-up (incidence rate ratios [95% confidence interval]: 1.35 [1.29-1.42], 1.22 [1.15-1.29], and 1.26 [1.19-1.34] for 0-5-, 6-11-, and 12-17-year-olds, respectively); the association persisted with SABA as a continuous variable and was stronger among patients without atopic diseases (32%-44% increased risk versus. 14%-21% for those with atopic disease across groups).
conclusionsHigh SABA use was associated with increased asthma exacerbation risk in children, particularly in those without comorbid atopic diseases, emphasizing the need for asthma medication reviews and reformative initiatives by caregivers and healthcare providers on SABA use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.